

EpigenoMax Therapeutics
400 Farmington Avenue,
Farmington, CT 06030

Xianyong (Max) Ma
T 203-9078908
www.epigenomax.com
info@epigenomax.com



Industry: Biotechnology startup

Management:

Xianyong (Max), Ma: Ph.D. (Cancer Biology) Founder, CEO.
Seeking to fill additional roles:
Chief Technology Officer
VP of Finance

Advisory Board:

Bijan Almossian, Ph.D. Co-Founder
CEO, CaroGen Corp.
Valerian Nakaar, Ph.D.
CaroGen Corp., Senior VP.
Dawn Alderman, ABS Bio, Director.

Scientific Advisory Board:

Jiangbin Zhou, Ph.D. Professor of
Neurosurgery, Gene Therapy.
Yale University School of Medicine.
Kepeng Wang, Ph.D. Professor of
Immunology, (Cancer Cell Therapy),
University of Connecticut.

Number of Employees: 3

Finance:

Accounting/Tax: TBD

Funding to Date: Founder: \$150K

Financing Sought: \$ 3M

For: R&D

Operating Costs
Overhead

IP: USPTO63/571,157 (2024-2025)

Patent owner Xianyong Ma

Seeking:

Software Copyright

Legal Consultant

Company Description / Background:

Snake venom proteins represent a promising treatment option for overcoming cancer resistance. EpigenoMax Therapeutics is dedicated to advancing an innovative drug platform called the "Precision Molecular Surgery Knife (PMSK)." This cutting-edge technology is engineered to precisely target late-stage cancers including stage IV colorectal cancer (CRC). Additionally, as a versatile platform, it holds the potential for treating progressive pancreatic cancer, triple-negative breast cancer, and other advanced malignancies. The company is committed to providing a transformative solution to address the significant unmet clinical needs in late-stage cancer treatment.

Problem:

Stage IV colorectal cancer, which has metastasized to other organs, typically lacks effective treatment options. The patients often face poor-to-no cure due to inherent resistance, recurrence, and low response rates to current options.

Solution:

Our PMSK platform promotes highly cell specific necrosis in cancer cells, effectively leading to their destruction and treatment through its powerful snake venom enzymatic hydrolysis of cancer cell components. To ensure specificity, PMSK was engineered by fusing the viral VSVG shell protein with cancer cell-specific antibody fragments (VHHs). This design enables precise targeting and powerful destruction of cancer cells.

Market:

For patients with stage IV colorectal cancer who have limited therapeutic options, the global market is \$5.2 billion in 2024 and projected to reach approximately \$6.4 billion by 2032. PMSK is expected to capture around 10% of this market in 5-10 years.

Competition / Competitive Advantage:

We have completed the proof-of-concept design and synthesis of PMSK, conducted in vitro efficacy and toxicity assays. Our PMSK drug effectively addresses the inherent issues of resistance, recurrence, and low response that are often encountered with other treatments.

Traction and Progress:

- A). the USPTO has provided a provisional patent for PMSK;
- B). completed the proof-of-concept design production of Ep-CA-101
- C). conducted in vitro efficacy and toxicity assays.
- D). submitted full proposal for NSF-SBIR I grant.

Future Plans and Milestones:

We will utilize patient-derived xenograft (PDX) mouse models to In Vivo evaluate the efficacy and safety; apply the FDA approval for clinic trials in 2028; move to market for clinic treatment and profit in 2032 as an independent company.

Financial Forecast (Unaudited):

	1st Year	2nd Year	3rd Year	4th Year	5th Year
Operating	(\$95,000)	(\$95,000)	(\$95,000)	(\$95,000)	(\$95,000)
R & D Expenses	(\$155,000)	(\$205,000)	(\$355,000)	(\$355,000)	(\$305,000)
Salary and others	(\$202,500)	(\$453,000)	(\$695,000)	(\$695,000)	(\$699,000)
Net Income	(\$455,000)	(\$753,000)	(\$1,145,000)	(\$1,145,000)	(\$1,099,000)